CJC-1295 + Ipamorelin Stack: The Complete Guide to Dosing, Benefits, and Results

If you've spent any time researching peptide therapy or growth hormone optimization, you've almost certainly come across the CJC-1295 and Ipamorelin combination. This stack has become one of the most popular peptide protocols in both clinical anti-aging medicine and the broader biohacking community—and for good reason. When used together, these two peptides produce a synergistic growth hormone (GH) pulse that neither can achieve alone.

This guide covers everything you need to know: how each peptide works, why the combination outperforms individual use, dosing protocols, expected benefits, side effects, and what the research actually says.

What Are CJC-1295 and Ipamorelin?

CJC-1295

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the endogenous signal that tells the pituitary gland to produce and release GH. The "without DAC" (Drug Affinity Complex) version—also called Modified GRF 1-29—has a half-life of approximately 30 minutes and produces a GH pulse that mimics the body's natural rhythm. The DAC version extends the half-life to 5–8 days, keeping GH levels persistently elevated.

A landmark clinical study published in the Journal of Clinical Endocrinology & Metabolism (Teichman et al., 2006) found that a single injection of CJC-1295 produced dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold lasting 6 days or more, and IGF-1 levels rose 1.5- to 3-fold for 9–11 days. With repeated dosing, IGF-1 remained elevated for up to 28 days. Crucially, "no serious adverse reactions were reported" across the study cohort.

Ipamorelin

Ipamorelin is a selective growth hormone secretagogue (GHS) and ghrelin receptor agonist. It belongs to the GHRP (growth hormone-releasing peptide) family but stands apart from older peptides like GHRP-6 and GHRP-2 in one critical way: it stimulates GH release without significantly raising cortisol, prolactin, or ACTH. This selectivity makes Ipamorelin one of the cleanest GH-stimulating peptides available.

Where CJC-1295 amplifies the signal (GHRH axis), Ipamorelin amplifies the response via a separate receptor pathway (ghrelin/GHS-R1a). The result when combined: both the amplitude and duration of the GH pulse are significantly enhanced—a synergy that single-peptide protocols can't replicate.

How the Stack Works: The Science of Synergy

The pituitary gland releases GH in pulses controlled by two opposing signals: GHRH (stimulatory) and somatostatin (inhibitory). CJC-1295 and Ipamorelin attack this system from two independent angles:

• CJC-1295 binds GHRH receptors on pituitary somatotrophs, increasing the number of cells ready to release GH and amplifying baseline GH output.
• Ipamorelin binds GHS-R1a receptors, triggering a rapid, acute GH spike and also suppressing somatostatin—the "brake" on GH secretion.

Together, they create a larger, more sustained pulse that more closely mimics the body's natural nocturnal GH surge. This dual-receptor approach is why the stack produces effects noticeably superior to either peptide used alone.

Benefits of the CJC-1295 + Ipamorelin Stack

Lean Muscle Growth

Elevated GH and downstream IGF-1 levels drive increased protein synthesis and nitrogen retention. Users and clinicians consistently report improvements in lean body mass, particularly when the protocol is paired with resistance training. This isn't rapid, dramatic mass gain—it's the gradual, quality muscle accumulation that comes from optimized GH pulsatility over weeks and months.

Fat Loss and Body Recomposition

GH is a potent lipolytic hormone—it mobilizes stored fat for use as fuel, particularly visceral and subcutaneous adipose tissue. Many users report visible changes in body composition within 8–12 weeks, especially in stubborn areas like the abdomen and lower back.

Deeper, More Restorative Sleep

GHRH activity is closely tied to slow-wave (deep) sleep. Users frequently report improved sleep quality as one of the first noticeable effects of the stack—falling asleep faster, sleeping more deeply, and waking with greater energy. This improvement in sleep architecture also accelerates muscle recovery and cognitive function.

Accelerated Recovery

Higher GH and IGF-1 levels support connective tissue repair, collagen synthesis, and cellular regeneration. Athletes and active individuals often notice reduced muscle soreness and faster recovery between training sessions.

Anti-Aging and Longevity Support

As a component of many longevity-focused protocols, CJC-1295/Ipamorelin is used to address the natural age-related decline in GH secretion (somatopause). Reported benefits include improved skin quality, higher energy levels, better cognitive clarity, and enhanced libido.

Dosing Protocol

The following represents commonly used clinical and research-informed dosing. Individual protocols should be tailored in consultation with a qualified healthcare provider.

Standard Dosing

• CJC-1295 without DAC (Mod GRF 1-29): 100 mcg per injection
• Ipamorelin: 200 mcg per injection
• Frequency: 1–2 injections per day
• Timing: Best administered at night, 30–60 minutes before bed, on an empty stomach (at least 2 hours post-meal). A second dose can be taken in the morning upon waking or pre-workout.
• Route: Subcutaneous injection into fatty tissue (abdomen, thigh, or flank)

Cycle Structure

• Standard cycle: 3 months on, 1–2 months off
• Extended protocols: Some clinicians use 5 days on / 2 days off to mimic natural GH pulsatility patterns
• Note: Allow sufficient off-cycle time to prevent pituitary desensitization

Why Timing Matters

GH is naturally secreted in pulses, with the largest pulse occurring 1–2 hours after sleep onset. Administering the stack before bed amplifies this physiological peak. Insulin blunts GH release, so fasted administration is essential—avoid high-carbohydrate or high-fat meals in the 2 hours preceding injection.

Side Effects and Safety Profile

The CJC-1295/Ipamorelin stack has a favorable safety profile relative to exogenous GH administration, but side effects do occur:

Common (typically transient)

• Water retention: Mild, usually resolves within the first 2–3 weeks as the body adjusts
• Injection site reactions: Redness, itching, or mild swelling at the injection site
• Flushing or tingling: A brief warm sensation shortly after injection, more common with Ipamorelin
• Mild nausea: Occasional and typically dose-dependent
• Lightheadedness: Usually occurs only in the first week

Less Common

• Carpal tunnel symptoms: High GH levels can cause fluid retention in the wrist—usually resolves with dose reduction
• Elevated blood glucose: GH has anti-insulin effects; users with insulin sensitivity concerns should monitor blood sugar
• Immune reactions: Rare risk of antibody formation, as with any peptide

What Ipamorelin Does NOT Do

One of Ipamorelin's key advantages over GHRP-6 and GHRP-2 is its clean selectivity. It does not significantly raise cortisol, prolactin, or ACTH—the hormonal side effects that limit older GHRPs. Appetite stimulation (a common GHRP-6 complaint) is also minimal with Ipamorelin.

Contraindications

• Active cancer or history of malignancy: GH and IGF-1 can stimulate cellular proliferation—absolute contraindication
• Uncontrolled diabetes: GH-induced insulin resistance may worsen glycemic control
• Severe cardiovascular disease
• Pregnancy and breastfeeding
• Competitive athletes: Both peptides are prohibited under WADA anti-doping regulations
• Active infections or severe inflammatory conditions

CJC-1295 With DAC vs. Without DAC

This is a common point of confusion:

• Without DAC (Mod GRF 1-29): ~30-minute half-life, produces a defined GH pulse that mirrors natural pulsatility. Preferred for most protocols—less risk of chronic GH elevation.
• With DAC: 5–8 day half-life, keeps GH levels continuously elevated. More convenient (dosed 1–2x per week) but may blunt the natural pulsatile pattern.

Most practitioners favor CJC-1295 without DAC for its physiological pulsatility and cleaner side-effect profile when combined with Ipamorelin.

What the Research Says

Direct human clinical trials on the combination are limited—most research studies each peptide individually—but the mechanistic rationale is well-established:

• The Teichman et al. (2006) CJC-1295 study demonstrated robust, sustained GH and IGF-1 elevation that was "safe and relatively well tolerated" in healthy adults.
• Ipamorelin's selectivity profile has been characterized in multiple preclinical and early-phase studies, consistently showing GH elevation without cortisol/prolactin side effects.
• The complementary receptor mechanisms (GHRH-R vs. GHS-R1a) provide a solid pharmacological basis for the synergistic clinical effects observed.

Most CJC-1295/Ipamorelin protocols are supported by clinical experience, pharmacological reasoning, and small observational studies rather than large randomized controlled trials—typical of the peptide space broadly.

Frequently Asked Questions

How long until I see results?

Sleep improvements are often noticed within the first 1–2 weeks. Body composition changes typically become visible at 6–8 weeks. Maximum benefits are generally seen after 3–6 months of consistent use.

Can I stack CJC-1295/Ipamorelin with other peptides?

Yes—common additions include BPC-157 for recovery, TB-500 for tissue repair, and Epithalon for longevity support. Avoid stacking with other GH secretagogues (like GHRP-6) to prevent receptor oversaturation.

Do I need to cycle off?

Yes. Extended continuous use can lead to pituitary desensitization. The standard 3 months on / 1–2 months off cycle is recommended to maintain receptor sensitivity.

Is this the same as HGH therapy?

No. CJC-1295 and Ipamorelin stimulate the pituitary to produce its own GH—they do not introduce exogenous human growth hormone. The body's natural feedback loops remain intact, which is a key safety advantage.

Conclusion

The CJC-1295 and Ipamorelin stack is one of the most scientifically rational peptide combinations available. By simultaneously stimulating two distinct GH release pathways, it produces amplified, pulsatile GH output that can support meaningful improvements in body composition, recovery, sleep quality, and overall wellness—without the blunt-force approach of exogenous HGH.

The favorable safety profile, particularly Ipamorelin's selectivity for GH over other hormones, makes this stack well-tolerated by most users when dosed correctly and cycled appropriately. As with all peptide protocols, work with a knowledgeable provider, monitor your labs (IGF-1, fasting glucose, thyroid function), and respect the contraindications.

This article is for educational purposes only and does not constitute medical advice. Peptide therapies should be used under the supervision of a qualified healthcare provider.